Antipsychotics

Mechanism of Action and Pharmacodynamics of Ziprasidone

By: Flavio Guzman, MD Mechanism of Action The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having…

Read More

Ziprasidone (Geodon) Indications: FDA-Approved Uses

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Indications and Usage GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first.…

Read More

Olanzapine Interactions

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic…

Read More

Olanzapine Adverse Effects

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Oral Olanzapine Monotherapy: Schizophrenia (Adults) – postural hypotension, constipation, weight gain, dizziness, personality disorder, akathisia Schizophrenia (Adolescents) – sedation, weight increased, headache, increased…

Read More

Mechanism of Action and Pharmacodynamics of Olanzapine

By: Flavio Guzman, MD Olanzapine is a second-generation antipsychotic that acts as antagonist at 5HT2A and D2 receptors. Mechanism of Action The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine…

Read More

Olanzapine Indications: FDA-Approved Uses

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Olanzapine (Zyprexa) is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. A combination of the antidepressant fluoxetine and olanzapine (OFC, olanzapine/fluoxetine combination) is also available under the trade name Symbyax. List of…

Read More

Olanzapine Pharmacokinetics

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Oral Administration Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose. It is eliminated extensively by first pass metabolism, with approximately 40% of the dose…

Read More

Iloperidone (Fanapt) Indications: FDA-Approved Uses

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Indications and Usage FANAPT® tablets are indicated for the treatment of adults with schizophrenia. Efficacy was established in two short-term (4- and 6-week) placebo- and active-controlled studies of adult patients with schizophrenia. When deciding among the…

Read More

Iloperidone (Fanapt) Drug Interactions

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Given the primary CNS effects of FANAPT, caution should be used when it is taken in combination with other centrally acting drugs and alcohol. Due to its α1-adrenergic receptor antagonism, FANAPT has the potential to enhance…

Read More

Iloperidone (Fanapt): Adverse Effects and Warnings

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Commonly observed adverse reactions (incidence ≥5% and two-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased Warnings and Precautions Increased Risks in Elderly Patients with Dementia-Related Psychosis…

Read More